Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$113.87 USD
-0.68 (-0.59%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $113.78 -0.09 (-0.08%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Cash flow Statements
Fiscal Year End for Jazz Pharmaceuticals PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 414.83 | -224.06 | -329.67 | 238.62 | 523.37 |
Depreciation/Amortization & Depletion | 638.70 | 629.47 | 552.48 | 334.91 | 416.55 |
Net Change from Assets/Liabilities | -204.44 | 9.90 | -47.95 | -85.44 | -150.08 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 242.92 | 856.66 | 603.64 | 411.56 | -13.43 |
Net Cash From Operating Activities | 1,092.01 | 1,271.98 | 778.51 | 899.65 | 776.40 |
Property & Equipment | -23.96 | -29.05 | -27.64 | -0.74 | -25.93 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 53.00 | -6,234.79 | 0.00 | -55.07 |
Investments | -120.10 | -1.04 | 1,068.18 | -642.68 | 67.90 |
Other Investing Activities | -19.00 | -469.15 | -17.89 | -364.25 | -142.20 |
Net Cash from Investing Activities | -163.06 | -446.23 | -5,212.14 | -1,007.67 | -155.30 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -223.30 | 97.97 | 135.26 | -46.86 | -243.62 |
Issuance (Repayment) of Debt | -31.00 | -582.01 | 3,870.86 | 591.81 | -33.39 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -50.95 | -45.44 | -35.60 | -16.88 | -16.74 |
Net Cash from Financing Activities | -305.25 | -529.49 | 3,970.52 | 528.07 | -293.75 |
Effect of Exchange Rate Changes | 1.14 | -6.22 | -3.21 | 0.37 | 0.37 |
Net Change In Cash & Equivalents | 624.83 | 290.03 | -466.32 | 420.43 | 327.72 |
Cash at Beginning of Period | 881.48 | 591.45 | 1,057.77 | 637.34 | 309.62 |
Cash at End of Period | 1,506.31 | 881.48 | 591.45 | 1,057.77 | 637.34 |
Diluted Net EPS | 6.10 | -3.58 | -5.52 | 4.22 | 9.09 |
Fiscal Year End for Jazz Pharmaceuticals PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 153.95 | -14.62 | 414.83 | 320.68 | 173.86 |
Depreciation/Amortization & Depletion | 326.42 | 163.38 | 638.70 | 479.50 | 15.09 |
Net Change from Assets/Liabilities | 29.59 | 56.40 | -204.44 | -23.43 | 1.12 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 88.62 | 62.06 | 242.92 | 147.93 | 427.41 |
Net Cash From Operating Activities | 598.58 | 267.23 | 1,092.01 | 924.67 | 617.47 |
Property & Equipment | -14.00 | -6.90 | -23.96 | -13.86 | -9.56 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -505.00 | -255.00 | -120.10 | -250.00 | -80.00 |
Other Investing Activities | -10.00 | -10.00 | -19.00 | -1.00 | -1.00 |
Net Cash from Investing Activities | -529.00 | -271.90 | -163.06 | -264.86 | -90.56 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -149.99 | 0.49 | -223.30 | -132.36 | -63.50 |
Issuance (Repayment) of Debt | -15.50 | -7.75 | -31.00 | -23.25 | -15.50 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -52.14 | -49.30 | -50.95 | -49.34 | -47.45 |
Net Cash from Financing Activities | -217.64 | -56.55 | -305.25 | -204.95 | -126.46 |
Effect of Exchange Rate Changes | -2.46 | -1.70 | 1.14 | -0.65 | 0.37 |
Net Change In Cash & Equivalents | -150.51 | -62.93 | 624.83 | 454.21 | 400.82 |
Cash at Beginning of Period | 1,506.31 | 1,506.31 | 881.48 | 881.48 | 881.48 |
Cash at End of Period | 1,355.80 | 1,443.39 | 1,506.31 | 1,335.69 | 1,282.30 |
Diluted Net EPS | 2.49 | -0.23 | 1.40 | 2.14 | 1.52 |